Abiopharma

🔍 LOTT RONALD M. (Director)

Company: SURO CAPITAL CORP. (SSSS)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Sold 10,669 shares of Common Stock at $12.9 per share (Direct)
  Date: 2026-04-28 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,669.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-28 | Code: H | shares_owned_after: 7,812.00 | Footnotes: F3

Footnotes:

• F1: The price reported in Column 4 is a weighted-average price, rounded to the nearest hundredth. The reporting person undertakes to provide upon request by the staff of the Securities and Exchange Commission, SuRo Capital Corp. (the "Company"), or a security holder of the Company's, full information regarding the number of shares sold at each separate price.
• F2: These shares are held of record by the Ronald M. Lott Family Trust dtd 3/9/1992 (the "Trust"), of which Mr. Lott is a trustee and beneficiary, and may be deemed to be beneficially owned by Mr. Lott. Mr. Lott disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest therein.
• F3: This total includes restricted shares granted under the SuRo Capital Corp. Second Amended and Restated 2019 Equity Incentive Plan, which vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being May 28, 2026) and (ii) the date of the Company's annual meeting of stockholders that is closest to the first anniversary of the award date.